CAS: 274694-98-3 - 7-methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine
Formula:C20H22N2
InChI:InChI=1/C20H22N2/c1-22-12-10-15-6-2-3-7-16(15)14-20-18(11-13-22)17-8-4-5-9-19(17)21-20/h2-9,21H,10-14H2,1H3
- Synonyms:
- 5H-Indolo[3,2-f][3]benzazecine, 6,7,8,9,14,15-hexahydro-7-methyl-
- 7-Methyl-6,7,8,9,14,15-hexahydro-5H-indolo[3,2-f][3]benzazecine
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
LE 300 REF: TM-T22921CAS: 274694-98-3 | 98.08% - 98.35% | 87.00 €~1,988.00 € | Tue 10 Dec 24 | |
LE300 REF: 4Z-L-216001CAS: 274694-98-3 | - - - | To inquire | Tue 17 Dec 24 | |
LE 300 REF: TR-L321003CAS: 274694-98-3 | - - - | 1,386.00 € | Tue 21 Jan 25 | |
LE 300 REF: 3D-ZKA69498CAS: 274694-98-3 | Min. 95% | To inquire | Tue 21 Jan 25 |
LE 300
CAS:274694-98-3
LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5)receptors …
Formula:
C20H22N2
Purity:
98.08% - 98.35%
Color and Shape:
Solid
Molecular weight:
290.4
Ref: TM-T22921
1mg | 87.00 € | ||
5mg | 206.00 € | ||
10mg | 306.00 € | ||
25mg | 512.00 € | ||
50mg | 730.00 € | ||
100mg | 994.00 € | ||
500mg | 1,988.00 € |
Estimated delivery in United States, on Tuesday 10 Dec 2024
Ref: 4Z-L-216001
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire | ||
100mg | To inquire |
Estimated delivery in United States, on Tuesday 17 Dec 2024
LE 300
Controlled ProductCAS:274694-98-3
Applications LE 300 is a potent and selective dopamine receptor antagonist. References Hefnawy, M., et …
Formula:
C20H22N2
Color and Shape:
Neat
Molecular weight:
290.4
Ref: TR-L321003
10mg | 1,386.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025
LE 300
CAS:274694-98-3
LE 300 is a peptide that belongs to the class of ligands. It is an …
Formula:
C20H22N2
Purity:
Min. 95%
Molecular weight:
290.41 g/mol
Ref: 3D-ZKA69498
1mg | To inquire | ||
2mg | To inquire | ||
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire |
Estimated delivery in United States, on Tuesday 21 Jan 2025